🧾 What This Document Is

This is a DEFA14A filing, which is a "definitive additional soliciting material." Think of it as the official, detailed brochure sent to shareholders to convince them to vote "YES" on a proposed corporate deal. Specifically, it announces that TruBridge, Inc. (TBRG) has agreed to be acquired by a company called Inventurus Knowledge Solutions, Inc. (IKS Health). This document outlines the entire deal, its terms, and why shareholders should approve it.

🏢 What The Company Does

👉 In simple terms, TruBridge is a healthcare technology company that helps hospitals and clinics manage their money and paperwork.

They specialize in "revenue cycle management" (RCM) – the complex process of getting paid by insurance companies and patients for medical services. Their tools help healthcare providers reduce administrative headaches, speed up claims, and improve cash flow. They are a key player in making the business side of healthcare run smoother.

🤝 The Deal: A $26.25 Per Share Buyout

On April 23, 2026, TruBridge signed a definitive merger agreement. Here are the core mechanics:

• The Buyer: Inventurus Knowledge Solutions, Inc. (IKS Health), a larger healthcare technology company. The deal is being executed through a subsidiary called IKS Next Horizon, Inc.
• The Price: TruBridge shareholders will receive $26.25 in cash for each share of common stock they own. This is the fixed "take-it-or-leave-it" offer.
• The Structure: It's a "merger." IKS Health's subsidiary will merge into TruBridge, with TruBridge surviving as a wholly-owned subsidiary of IKS Health. TruBridge will no longer be a publicly traded company.
• Employee Awards: Existing restricted stock and performance share awards for employees will be converted into cash payments based on the $26.25 price.
• Key Shareholder Support: Major shareholders (L6 Holdings, Pinetree Capital, and Ocho Investments) who collectively own about 27% of TruBridge stock have already signed agreements to vote their shares in favor of the deal.

⚖️ The Rules of the Game: Conditions & Fees

A merger isn't automatic. Several conditions must be met, and there are financial penalties if either side walks away improperly.

Key Conditions:

• TruBridge shareholders must vote to approve the merger.
• Regulatory approvals, including a review under the Hart-Scott-Rodino (HSR) Antitrust Act, must be obtained or waived.
• No laws can be in place that block the deal.
• TruBridge's business cannot suffer a major negative change ("Material Adverse Effect") before closing.

Termination Fees (The "Breakup" Penalties):

• TruBridge's Fee: If TruBridge accepts a better offer from someone else ("Superior Proposal"), it must pay IKS Health a fee of $12,292,875.
• IKS Health's Fee (Reverse Termination Fee): In specific scenarios, like if IKS cannot get necessary shareholder approvals in India for its financing, it must pay TruBridge $24,585,750.

📅 What's Next & Key Dates

The deal isn't done yet. Here’s the likely timeline:

• A proxy statement will be filed with the SEC and sent to shareholders, outlining how and when to vote.
• A shareholder meeting will be held for the vote.
• The deal is expected to close in the second half of 2026.
• The agreement has an "Outside Date" of October 23, 2026. If the merger isn't finished by then, either side can walk away.

🔮 What This Signals for the Industry

This deal is a classic example of consolidation in the healthcare tech sector. IKS Health is acquiring TruBridge to broaden its platform and customer base. For TruBridge, it represents a sale at a fixed price, giving shareholders immediate value. For the industry, it suggests that scale and integrated service offerings (like combining clinical and financial tech) are becoming increasingly valuable.

👍 The Strengths & ⚠️ The Risks

👍 Strengths of the Deal:

• Premium & Certainty: Shareholders get a guaranteed cash price, removing stock market uncertainty.
• Strong Support: Backing from major shareholders (27% ownership) makes approval more likely.
• Strategic Fit: IKS Health is a logical buyer in the same industry, suggesting operational synergies.

⚠️ Risks & Uncertainties:

• Regulatory Hurdle: The HSR antitrust review could cause delays or, in a worst case, block the deal.
• No Better Offer: Once signed, TruBridge is in a "go-shop" period that is now over, making it hard to attract a higher bidder. The breakup fee also discourages competing offers.
• Financing Dependency: While IKS has debt financing lined up, the final approval from its Indian shareholders is a condition, adding a layer of execution risk.

🧠 The Analogy

Imagine a well-regarded local restaurant (TruBridge) that's great at handling its own complex bookings and finances. A larger, national restaurant group (IKS Health) decides to buy it. The group will pay the local owner's family a set cash price for their shares. The local restaurant will keep its name and staff but will now use the big group's suppliers, accounting systems, and purchasing power. The deal is a good exit for the family, but it needs approval from all the family members and a sign-off from the city (regulators) to make sure the big group isn't becoming a monopoly.

🧩 Final Takeaway

TruBridge is being acquired by IKS Health for $26.25 per share in cash, pending shareholder and regulatory approval. This is a strategic consolidation move in healthcare tech, offering TruBridge shareholders a clear cash exit while combining two companies' expertise in medical administration and revenue management.